Company Profile - Agios Pharmaceuticals Inc


Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company. The company focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. Its pipeline products include AG-946, a novel, next-generation PKR activator used for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low- to intermediate-risk myelodysplastic syndrome. The company also provides Mitapivat which is an activator of both wild-type and a variety of mutant pyruvate kinase that is used against hemolytic anemias. Agios is headquartered in Cambridge, Massachusetts, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 1,444
Revenue (US$ m): 14 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

Agios Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers